---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-207423"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:40:08.162735+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q2 revenue $99.6M, GAAP EPS $0.33 (vs $0.20), raises FY2023 guide to $380M-$390M

## Summary
- Q2 net product revenue $99.5M: FIRDAPSE $64.9M (+22% YoY); FYCOMPA $34.6M first-time contribution.
- GAAP net income $37.8M, diluted EPS $0.33; Non-GAAP net income $60.4M, diluted EPS $0.53.
- Raised FY2023 total revenue guidance to $380M-$390M.
- Closed acquisition of North American vamorolone license for $75M in July; $15M Santhera equity investment and $10M Ruzurgi installment paid post-Q2.
- Submitted sNDA for FIRDAPSE to increase maximum indicated dose to 100 mg/day.

## SEC filing metadata
- accession: 0001193125-23-207423
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/0001193125-23-207423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/d497533d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-207423
- JSON: https://secwatch.observer/filing/0001193125-23-207423.json
- Plain text: https://secwatch.observer/filing/0001193125-23-207423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.